Compare AT&T Inc. (T) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? AT&T Inc. trades at $22.18 (market cap $170.42B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: AT&T Inc. is far larger — about 16.9× State Street SPDR S&P Biotech ETF's market cap, and AT&T Inc. pays a 4.46% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold AT&T Inc. for 118 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| T | XBI | |
|---|---|---|
Market Cap | $170.42B | $10.11B |
Volume | 50,780,036 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $29.10 | $169.55 |
52-Week Low | $20.49 | $104.99 |
Typical Hold Time | 118 Days | 38 Days |
Enterprise Value | $315.74B | — |
Dividend Yield | 4.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $24.885, up 1.68% today, with a bullish technical signal overall despite mixed moving averages and oscillators. The company shows strong fundamentals with a P/E of 8.21, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights a $3 billion fiber deal with Corning and a joint venture with T-Mobile and Verizon to expand coverage.
The outlook is positive with a consensus price target of $27.50, offering potential upside. Key risks include high debt levels and competitive pressures. The stock presents a value opportunity with a solid dividend, but investors should monitor debt management and revenue growth sustainability.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
